Abbott Receives CE Mark for First Dual Glucose-Ketone Sensor to Prevent Diabetic Ketoacidosis
Key Insights
Abbott (search) has received Europe's CE mark for the first dual-analyte sensor capable of continuously monitoring both glucose and ketones, marking a significant advancement in diabetes management technology.
The Libre Duo systems are designed to help detect rising ketone levels that can signal diabetic ketoacidosis, a life-threatening condition that hospitalized more than four times as many people as hypoglycemia in 2021.
The technology eliminates the need for traditional blood or urine ketone testing and will launch in European countries this year, with U.S. FDA approval expected in the second half of 2024.
Abbott (search) has achieved a significant milestone in diabetes management technology by receiving Europe's CE mark for the world's first dual-analyte sensor that can simultaneously measure both glucose and ketones. The groundbreaking technology addresses a critical gap in diabetes care by providing continuous monitoring capabilities that could help prevent diabetic ketoacidosis, a life-threatening condition caused by insulin deficiency.
Revolutionary Dual-Sensor Technology
The newly approved systems, branded as Libre Duo and Libre Duo 10 Day, represent a major advancement from traditional single-analyte glucose monitors. The Libre Duo offers a 15-day wear time for adults aged 18 and older, while the Libre Duo 10 Day is designed for patients aged two and older. Abbott (search) plans to launch these systems in select European countries this year.
The technology eliminates the need for traditional blood or urine tests typically required to check ketone levels. People with diabetes are currently recommended to test for ketones during periods of illness, when the body releases hormones that can elevate blood sugar levels and potentially trigger dangerous complications.
Addressing Critical Medical Need
Diabetic ketoacidosis poses a significant healthcare challenge, with early symptoms such as nausea and fatigue often mistaken for other illnesses, leading to delayed recognition and treatment. According to the Centers for Disease Control and Prevention, more than four times as many people were hospitalized for hyperglycemic crises than hypoglycemia in 2021, highlighting the urgent need for better monitoring solutions.
Abbott (search) CEO Robert Ford first outlined the company's vision for multi-analyte sensors during a presentation at the Consumer Electronics Show in 2022, describing plans for devices capable of tracking glucose, ketones, and lactate. The realization of this technology represents a significant step forward in personalized diabetes management.
Regulatory Progress and Market Expansion
The CE mark approval enables Abbott (search) to begin marketing the dual-analyte sensor across Europe. The system is currently under review by the U.S. Food and Drug Administration, with Ford indicating to investors in April that the company expects approval in the second half of 2024.
The technology's data-sharing capabilities allow users to transmit glucose and ketone information to caregivers and healthcare providers, facilitating more comprehensive diabetes management. Abbott (search) is also collaborating with insulin pump manufacturers to enable automated insulin delivery systems to connect with the Libre Duo devices, potentially creating integrated treatment ecosystems.
Industry Context and Competition
The authorization follows collaborative efforts by key stakeholders, including nonprofit Breakthrough T1D (search), to establish best practices for continuous ketone monitoring. While competitor Dexcom (search) has also discussed dual-analyte sensing capabilities, the company's continuous ketone monitoring plans remain further out on the development timeline.
Dexcom (search) has indicated a different strategic focus, planning to concentrate on glucose and potassium monitoring to support patients with both diabetes and chronic kidney disease. This divergent approach highlights the various pathways companies are pursuing in the evolving continuous monitoring landscape.
The successful development and approval of Abbott (search)'s dual-sensor technology represents a significant advancement in diabetes care, offering patients and healthcare providers unprecedented real-time insights into both glucose levels and ketone production, potentially preventing serious complications and improving overall disease management outcomes.